

Shadab Ansari

From: Manish Oberoi <manishoberoi@market-xcel.com>
Sent: 20 December 2022 17:53
To: 'Rio Dabre'
Cc: 'Steven Lo'; 'Sofie Ng'; 'Leo Pattinama'; 'Kapil Narang'; amit@market-xcel.com; 'Shilpa Gupta'; shadab.ansari@market-xcel.com; 'Sarita Prasad'
Subject: RE: RE:-(P22-65846) CKD Overview | Nephrologists - MXL

Dear Rio,

Greetings for the day! Thank you for the email.

As discussed, my colleague Shadab Ansari will be leading this from our end request you to please keep him copied in further communication.

Thanks & Regards

Manish Oberoi
Sr. Manager – Client Services



Market Xcel Data Matrix Pvt. Ltd.
Extension: 505 / Direct Line: +91 11 42343 505 / Mobile: +91 9958 234 888

Follow us on



From: Rio Dabre <rdabre@glgroup.com>
Sent: 20 December 2022 17:18
To: manishoberoi@market-xcel.com; Sarita Prasad <sprasad@glgroup.com>
Cc: rfp@market-xcel.com; Steven Lo <slo@glgroup.com>; Sofie Ng <sofie.ng@glgroup.com>; Leo Pattinama <vpattinama@glgroup.com>
Subject: RE: RE:-(P22-65846) CKD Overview | Nephrologists - MXL

Hi Manish,

Here's the draft. We need to close before Saturday.

Sending links shortly for testing. Kindly loop me with PM on this. As discussed, this is super urgent one and time sensitive survey. Hoping for your support to pull this off!

Regards,
Rio Dabre

From: Manish Oberoi <manishoberoi@market-xcel.com>
Sent: Friday, December 9, 2022 1:50 PM

To: Sarita Prasad <sprasad@glgroup.com>

Cc: rfp@market-xcel.com; Steven Lo <slo@glgroup.com>; Sofie Ng <sofie.ng@glgroup.com>; Leo Pattinama <vpattinama@glgroup.com>

Subject: RE:-(P22-65846) CKD Overview | Nephrologists - MXL

Dear Sarita,

Thank you for coming on call, as discussed, we are feasible for the below scope and pleased to share our proposal for the study.

CKD Overview	
Speciality	Nephrologist
Methodology	Quant-F2F
Geo	Suggested Metros
LOI	25-30 mints
Sample	20
CPI-\$	55
Total Cost-\$	1100
Timelines	Days
Set-up	2
Fieldwork Days	7

We look forward to hear from you and accordingly we shall take this forward.

Thanks & Regards

Manish Oberoi
Sr. Manager – Client Services



Market Xcel Data Matrix Pvt. Ltd.
Extension: 505 / Direct Line: +91 11 42343 505 / Mobile: +91 9958 234 888

Follow us on



From: Manish Oberoi <manishoberoi@market-xcel.com>
Sent: 09 December 2022 11:31
To: 'Sarita Prasad' <sprasad@glgroup.com>
Cc: 'rfp@market-xcel.com' <rfp@market-xcel.com>; 'Steven Lo' <slo@glgroup.com>; 'Sofie Ng' <sofie.ng@glgroup.com>; 'Leo Pattinama' <vpattinama@glgroup.com>
Subject: RE: CKD Overview | Nephrologists - MXL

Sure will work around the same.

Thanks & Regards

Manish Oberoi
Sr. Manager – Client Services



Market Xcel Data Matrix Pvt. Ltd.
Extension: 505 / Direct Line: +91 11 42343 505 / Mobile: +91 9958 234 888

Follow us on



From: Sarita Prasad <sprasad@glgroup.com>
Sent: 09 December 2022 11:27
To: manishoberoi@market-xcel.com
Cc: rfp@market-xcel.com; Steven Lo <slo@glgroup.com>; Sofie Ng <sofie.ng@glgroup.com>; Leo Pattinama <vpattinama@glgroup.com>
Subject: RE: CKD Overview | Nephrologists - MXL

Please note, expert should qualify all 3 screening criteria.

Sarita Prasad

Senior Associate – APAC Panel



Unit 63, 6th Floor, 2 North Avenue Maker Maxity
Bandra Kurla Complex Mumbai- 400051 India
M +91 9768042369
sprasad@glgroup.com
glginsights.com

From: Manish Oberoi <manishoberoi@market-xcel.com>

Sent: 09 December 2022 11:25

To: Sarita Prasad <sprasad@glgroup.com>

Cc: rfp@market-xcel.com; Steven Lo <slo@glgroup.com>; Sofie Ng <sofie.ng@glgroup.com>; Leo Pattinama <vpattinama@glgroup.com>

Subject: RE: CKD Overview | Nephrologists - MXL

Dear Sarita,

Thank you for reaching out with new request. Allow me sometime to work around the feasibility and shall come back to you with the cost on this.

Thanks & Regards

Manish Oberoi

Sr. Manager – Client Services



Market Xcel Data Matrix Pvt. Ltd.

Extension: 505 / Direct Line: +91 11 42343 505 / Mobile: +91 9958 234 888

Follow us on



From: Sarita Prasad <sprasad@glgroup.com>
Sent: 09 December 2022 11:20
To: Manish Oberoi <manishoberoi@market-xcel.com>
Cc: rfp@market-xcel.com; Steven Lo <slo@glgroup.com>; Sofie Ng <sofie.ng@glgroup.com>; Leo Pattinama <vpattinama@glgroup.com>
Subject: CKD Overview | Nephrologists - MXL
Importance: High

Hi Manish,

Please find below new specs. Kindly cost and feasibility as soon as possible.

Target audience - Nephrologist

Screening -

- Please eliminate physicians who treat <150 patients per month
- Please eliminate physicians who treat <50 patients per month for early stages of CKD, i.e. Stages 1, 2 and 3
- Please eliminate physicians who treat <100 patients per month for late stages of CKD, i.e. Stages 4 and 5 (at least 50% of these 100 patients should be on dialysis)

Geo- India

N-20

LOI-25-30 mins

Script will most likely have 20% Numerical OE questions

Please feel free to reach out to me if you have questions.

Sarita Prasad

Senior Associate – APAC Panel



Unit 63, 6th Floor, 2 North Avenue Maker Maxity
Bandra Kurla Complex Mumbai- 400051 India
M +91 9768042369
sprasad@glgroup.com
glginsights.com

Information and attachments in this email, are intended only for the person or entity to which it is addressed and may contain information that is confidential, privileged and subject to legal restrictions and penalties regarding its unauthorized disclosure and use. Any review, re-transmission, dissemination, disclosure of distribution by persons or entities other than the intended recipient is prohibited. If you are not the intended recipient, please notify the sender by reply email and delete the original message and all copies. Check for viruses before opening any emails or attachments. Opinions, conclusions and other information in this document that do not relate to the business of Gerson Lehrman Group, Inc. or its affiliates (collectively, "GLG") are neither given nor endorsed by it. For information regarding how GLG processes your information, please visit our privacy policy at <https://glginsights.com/privacy-policy/>.

Information and attachments in this email, are intended only for the person or entity to which it is addressed and may contain information that is confidential, privileged and subject to legal restrictions and penalties regarding its unauthorized disclosure and use. Any review, re-transmission, dissemination, disclosure of distribution by persons or entities other than the intended recipient is prohibited. If you are not the intended recipient, please notify the sender by reply email and delete the original message and all copies. Check for viruses before opening any emails or attachments. Opinions, conclusions and other information in this document that do not relate to the business of Gerson Lehrman Group, Inc. or its affiliates (collectively, "GLG") are neither given nor endorsed by it. For information regarding how GLG processes your information, please visit our privacy policy at <https://glginsights.com/privacy-policy/>.

Information and attachments in this email, are intended only for the person or entity to which it is addressed and may contain information that is confidential, privileged and subject to legal restrictions and penalties regarding its unauthorized disclosure and use. Any review, re-transmission, dissemination, disclosure of distribution by persons or entities other than the intended recipient is prohibited. If you are not the intended recipient, please notify the sender by reply email and delete the original message and all copies. Check for viruses before opening any emails or attachments. Opinions, conclusions and other information in this document that do not relate to the business of Gerson Lehrman Group, Inc. or its affiliates (collectively, "GLG") are neither given nor endorsed by it. For information regarding how GLG processes your information, please visit our privacy policy at <https://glginsights.com/privacy-policy/>.
